Search results for "INHIBITOR"

showing 10 items of 3742 documents

Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells

2016

Recent evidence has reported that proton pump inhibitors (PPIs) can exert antineoplastic effects through the disruption of pH homeostasis by inhibiting vacuolar ATPase (H+-VATPase), a proton pump overexpressed in several tumor cells, but this aspect has not been deeply investigated in EAC yet. In the present study, the expression of H+-VATPase was assessed through the metaplasia-dysplasia-adenocarcinoma sequence in Barrett’s esophagus (BE) and the antineoplastic effects of PPIs and cellular mechanisms involved were evaluated in vitro. H+-VATPase expression was assessed by immunohistochemistry in paraffined-embedded samples or by immunofluorescence in cultured BE and EAC cell lines. Cells we…

0301 basic medicineesophageal adenocarcinomaIntracellular pHvacuolar ATPaseBiologymedicine.disease_causeBarrett's esophagus03 medical and health sciencesmedicineBarrett’s esophagusCytotoxic T cellPharmacology (medical)Original Researchreactive oxygen speciesPharmacologychemistry.chemical_classificationReactive oxygen specieslcsh:RM1-950AutophagyProton Pump InhibitorsIn vitrolcsh:Therapeutics. Pharmacology030104 developmental biologyBiochemistrychemistryCell cultureApoptosisCancer researchEsophageal adenocarcinomaproton pump inhibitorsReactive Oxygen SpeciesOxidative stressFrontiers in Pharmacology
researchProduct

Heat Shock Proteins in Alzheimer’s Disease: Role and Targeting

2018

Among diseases whose cure is still far from being discovered, Alzheimer’s disease (AD) has been recognized as a crucial medical and social problem. A major issue in AD research is represented by the complexity of involved biochemical pathways, including the nature of protein misfolding, which results in the production of toxic species. Considering the involvement of (mis)folding processes in AD aetiology, targeting molecular chaperones represents a promising therapeutic perspective. This review analyses the connection between AD and molecular chaperones, with particular attention toward the most important heat shock proteins (HSPs) as representative components of the human chaperome: Hsp60,…

0301 basic medicineheat shock proteinDiseaseReviewprotein TauHsp70lcsh:ChemistrychaperoneEnzyme Inhibitorslcsh:QH301-705.5SpectroscopybiologyGeneral MedicineHsp60Hsp90Computer Science Applicationsamyloid peptideModels AnimalHSP60Protein foldingAlzheimer’s diseaseheat shock proteins; chaperones; Alzheimer’s disease; amyloid peptide; protein Tau; Hsp60; Hsp70; Hsp90Tau proteintau ProteinsHsp90Computational biologyCatalysisInorganic ChemistryMitochondrial Proteins03 medical and health sciencesAlzheimer DiseaseHeat shock proteinAnimalsHumanschaperonesHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsPhysical and Theoretical ChemistryMolecular BiologyAmyloid beta-PeptidesSettore BIO/16 - Anatomia UmanaOrganic ChemistryChaperonin 60Settore CHIM/06 - Chimica OrganicaHsp70030104 developmental biologylcsh:Biology (General)lcsh:QD1-999heat shock proteinsbiology.protein
researchProduct

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

2021

Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and age…

0301 basic medicinehepatotoxicityNevirapineEfavirenzQH301-705.5030106 microbiologyEtravirinecARTReviewBioinformaticsliver03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineDoravirinemedicineAnimalsHumans030212 general & internal medicineBiology (General)antiretroviral drugsbusiness.industryFatty livervirus diseasesHIVGeneral Medicinemedicine.diseasechemistryRilpivirineChronic DiseaseReverse Transcriptase InhibitorsDrug Therapy CombinationDILIChemical and Drug Induced Liver InjuryViral hepatitisbusinessmedicine.drugCells
researchProduct

New 3-Aryl-2-(2-Thienyl)acrylonitriles with High Activity against Hepatoma Cells

2021

New 2-(thien-2-yl)-acrylonitriles with putative kinase inhibitory activity were prepared and tested for their antineoplastic efficacy in hepatoma models. Four out of the 14 derivatives were shown to inhibit hepatoma cell proliferation at (sub-)micromolar concentrations with IC50 values below that of the clinically relevant multikinase inhibitor sorafenib, which served as a reference. Colony formation assays as well as primary in vivo examinations of hepatoma tumors grown on the chorioallantoic membrane of fertilized chicken eggs (CAM assay) confirmed the excellent antineoplastic efficacy of the new derivatives. Their mode of action included an induction of apoptotic capsase-3 activity, whil…

0301 basic medicinelcsh:Chemistry0302 clinical medicinelcsh:QH301-705.5SpectroscopyMolecular StructureKinaseChemistryLiver NeoplasmsGeneral MedicineHep G2 CellshepatomaComputer Science ApplicationsCAM assayMolecular Docking SimulationChorioallantoic membraneBiochemistry030220 oncology & carcinogenesistyrphostinTyrosine kinasemedicine.drugSorafenibCarcinoma HepatocellularthiopheneThiophenesCatalysisArticleInorganic ChemistryVEGFR inhibition03 medical and health sciencesStructure-Activity RelationshipIn vivomedicineHumansPhysical and Theoretical ChemistryMode of actionMolecular BiologyProtein Kinase InhibitorsCell ProliferationAcrylonitrileDose-Response Relationship DrugOrganic Chemistrymolecular dockingVascular Endothelial Growth Factor Receptor-2anticancer drugs030104 developmental biologylcsh:Biology (General)lcsh:QD1-999ApoptosisDocking (molecular)Drug Screening Assays AntitumorInternational Journal of Molecular Sciences
researchProduct

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

2019

Visual Abstract

0301 basic medicinelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyCardiac & Cardiovascular Systemsempagliflozinheart failure030204 cardiovascular system & hematologySGLT2i sodium-glucose co-transporter 2 inhibitorHF heart failurePRECLINICAL RESEARCH03 medical and health sciences0302 clinical medicineDM diabetes mellitusDiabetes mellitusInternal medicinemedicineEmpagliflozinMI-HF post-infarct heart failureGlycemicScience & TechnologyEjection fractionbusiness.industryNHE sodium-hydrogen exchangerANN artificial neural networkmedicine.diseaseHFrEF HF with reduced ejection fractionBlockadeXIAPmachine learning030104 developmental biologyMechanism of actionlcsh:RC666-701Heart failureCardiovascular System & CardiologyCardiologyRNAseq RNA sequencingempagtiflozinmedicine.symptomCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineJACC: Basic to Translational Science
researchProduct

Nitration of Wheat Amylase Trypsin Inhibitors Increases Their Innate and Adaptive Immunostimulatory Potential

2018

Amylase trypsin inhibitors (ATI) can be found in all gluten containing cereals and are, therefore, ingredient of basic foods like bread or pasta. In the gut ATI can mediate innate immunity via activation of the Toll-like receptor 4 (TLR4) on immune cells residing in the lamina propria, promoting intestinal, as well as extra-intestinal, inflammation. Inflammatory conditions can induce formation of peroxynitrite (ONOO-) and, thereby, endogenous protein nitration in the body. Moreover, air pollutants like ozone (O3) and nitrogen dioxide (NO2) can cause exogenous protein nitration in the environment. Both reaction pathways may lead to the nitration of ATI. To investigate if and how nitration mo…

0301 basic medicinelcsh:Immunologic diseases. AllergyCell SurvivalT cellnon-celiac wheat sensitivityImmunologyInflammationAdaptive ImmunityImmunophenotyping03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemprotein nitrationT-Lymphocyte SubsetsNitrationCell Line TumorwheatmedicineImmunology and AllergyHumansamylase trypsin inhibitorsTriticumPlant ProteinsOriginal ResearchInnate immune systemMacrophagesfood and beveragesDendritic CellsTetranitromethaneallergyImmunity InnateToll-Like Receptor 4030104 developmental biologymedicine.anatomical_structurechemistryBiochemistryAmylasesTLR4Cytokinesmedicine.symptomlcsh:RC581-607Trypsin InhibitorsPeroxynitriteBiomarkers030215 immunologyFrontiers in immunology
researchProduct

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA

2017

Jay Amin Hydroxamic Acid (JAHA; N8-ferrocenylN1-hydroxy-octanediamide) is a ferrocene-containing analogue of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA). JAHA’s cytotoxic activity on MDA-MB231 triple negative breast cancer (TNBC) cells at 72 h has been previously demonstrated with an IC50 of 8.45 M. JAHA’s lethal effect was found linked to perturbations of cell cycle, mitochondrial activity, signal transduction and autophagy mechanisms. In order to glean novel insights on how MDA-MB231 breast cancer cells respond to the cytotoxic effect induced by JAHA, and to compare the biological effect with the related compound SAHA, we have employed a combination of…

0301 basic medicinemedicine.drug_classAntineoplastic AgentsTriple Negative Breast NeoplasmsBiologyHydroxamic AcidsToxicologyStructure-Activity Relationship03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansCytotoxic T cellFerrous CompoundsSettore BIO/06 - Anatomia Comparata E Citologiaskin and connective tissue diseasesVorinostatTriple-negative breast cancerVorinostatDose-Response Relationship DrugHistone deacetylase inhibitorComputational BiologyGeneral MedicineTriple Negative Breast NeoplasmsCell cycleHistone Deacetylase InhibitorsSettore BIO/18 - Genetica030104 developmental biologyBiochemistryCell culture030220 oncology & carcinogenesisCancer researchHistone deacetylaseJAHA Comet assay MDA-MB231 Histone Deacetylase InhibitorsDrug Screening Assays Antitumormedicine.drug
researchProduct

Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.

2020

Epigenetic modifiers provide a new target for the development of anti-cancer drugs. The eraser histone deacetylase 6 (HDAC6) is a class IIb histone deacetylase that targets various non-histone proteins such as transcription factors, nuclear receptors, cytoskeletal proteins, DNA repair proteins, and molecular chaperones. Therefore, it became an attractive target for cancer treatment. In this study, virtual screening was applied to the MicroCombiChem database with 1162 drug-like compounds to identify new HDAC6 inhibitors. Five compounds were tested in silico and in vitro as HDAC6 inhibitors. Both analyses revealed 1-cyclohexene-1-carboxamide, 2-hydroxy-4,4-dimethyl-N-1-naphthalenyl-6-oxo- (MC…

0301 basic medicinemedicine.drug_classDNA repairAntineoplastic AgentsApoptosisHistone Deacetylase 6MicrotubulesEpigenesis Genetic03 medical and health sciences0302 clinical medicineCell MovementTubulinNeoplasmsCyclohexenesmedicineAnimalsHumansNeoplasm InvasivenessEpigeneticsHSP90 Heat-Shock ProteinsTranscription factorZebrafishPharmacologyChemistryHistone deacetylase inhibitorCell migrationAcetylationHDAC6Xenograft Model Antitumor AssaysCell biologyHistone Deacetylase Inhibitors030104 developmental biologyCell culture030220 oncology & carcinogenesisMCF-7 CellsHistone deacetylaseApoptosis Regulatory ProteinsPharmacological research
researchProduct

Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment.

2020

The deregulation of a wide variety of protein kinases is associated with cancer cell initiation and tumor progression. Owing to their indispensable function in signaling pathways driving malignant cell features, protein kinases constitute major therapeutic targets in cancer. Over the past two decades, intense efforts in drug development have been dedicated to this field. The development of protein kinase inhibitors (PKIs) have been a real breakthrough in targeted cancer therapy. Despite obvious successes across patients with different types of cancer, the development of PKI resistance still prevails. Combination therapies are part of a comprehensive approach to address the problem of drug r…

0301 basic medicinemedicine.drug_class[SDV]Life Sciences [q-bio]Nitric OxideBiochemistry03 medical and health sciences0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNitric Oxide DonorsMolecular Targeted TherapyProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryKinaseCancerProtein kinase inhibitormedicine.disease3. Good health030104 developmental biologyDrug developmentTumor progressionDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellCancer researchSignal transductionbusinessProtein KinasesSignal TransductionBiochemical pharmacology
researchProduct